The Chronic Kidney Disease Drugs Market involves drugs that can slow the progression of Chronic Kidney Disease and help manage associated complications. Chronic Kidney Disease (CKD) is a gradual loss of kidney function over time. Some of the main drugs used in the treatment of CKD include ACE inhibitors, Angiotensin II receptor blockers, Erythropoiesis-stimulating agents (ESAs), Calcium channel blockers, and Phosphate binders. These drugs aim to control blood pressure and anemia, reduce protein in the urine, lower phosphate levels, and slow down the progression of kidney damage in patients.

The Global Chronic Kidney Disease Drugs Market is estimated to be valued at US$ 17.9 billion in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024-2029.

Key Takeaways
Key players operating in the Chronic Kidney Disease Drugs are Amgen Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, AbbVie, Sanofi, Pfizer Inc., Keryx Biopharmaceuticals, Kissei Pharmaceutical Co., Ltd., Astellas Pharma Inc., and Johnson & Johnson.

The growing prevalence of diabetes, hypertension, and other chronic diseases leading to kidney damage has accelerated the demand for Chronic Kidney Disease Drugs Market Trends in recent years. As per the data by the International Society of Nephrology, around 850 million people are expected to be living with kidney diseases by 2030.

Get More Insights On- Chronic Kidney Disease Drugs Market